Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer
- PMID: 27048011
Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer
Abstract
Purpose: To evaluate the efficacy of intralipid intravenous infusion in achieving a live pregnancy following IVF--embryo transfer in women of advanced reproductive age (40-42 years).
Materials and methods: A matched control was performed. Women aged 40-42 with a previous history of miscarriage or who failed to conceive despite previous embryo transfer who entered an IVF program were offered intravenous intralipid therapy (four ml of 20% liposyn II in 100 ml normal saline over one hour) during the mid-follicular phase. Clinical pregnancy rates (eight weeks with viable gestation) and live delivered pregnancy rates were then determined and compared.
Results: The results were evaluated after ten matched cycles. There were no clinical pregnancies in those receiving intralipid vs. a 40% clinical and a 30% live delivered pregnancy rate in the untreated controls (p = 0.087, Fisher's exact test). The study was terminated because of these preliminary data.
Conclusions: In the test tube, adding intralipid to natural killer cells can inhibit their cytolytic action. However, the use of intravenous intralipid to suppress natural killer cell activity does not seem to improve the chance of a live delivery in women aged 40-42 years with a previous history of miscarriage. In fact this therapy may actually be detrimental in this age group. Since efficacy of this therapy was not found in a group of advanced reproductive age, it is not clear why this should be effective for a younger population. A controlled study for the younger group is needed. Perhaps such a study could be limited to only those with miscarriage rather than also concluding failure to conceive despite embryo transfer. Intralipid failed to improve live delivered pregnancy rates in women with prior miscarriage or previous failure with embryo transfer.
Similar articles
-
Intralipid therapy and adverse reproductive outcome: is there any evidence?Reprod Fertil. 2021 Jun 3;2(3):173-186. doi: 10.1530/RAF-20-0052. eCollection 2021 Jul. Reprod Fertil. 2021. PMID: 35118388 Free PMC article.
-
The effect of administration of intravenous intralipid on pregnancy outcomes in women with implantation failure after IVF/ICSI with non-donor oocytes: A randomised controlled trial.Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:45-51. doi: 10.1016/j.ejogrb.2019.06.007. Epub 2019 Jun 13. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31228675 Clinical Trial.
-
Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation.J Reprod Immunol. 2018 Nov;130:18-22. doi: 10.1016/j.jri.2018.09.050. Epub 2018 Sep 24. J Reprod Immunol. 2018. PMID: 30286362
-
Intralipid treatment for women with reproductive failures.Am J Reprod Immunol. 2021 Apr;85(4):e13290. doi: 10.1111/aji.13290. Epub 2020 Jul 8. Am J Reprod Immunol. 2021. PMID: 32567756 Review.
-
Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells.Int J Gynaecol Obstet. 2016 Dec;135(3):324-327. doi: 10.1016/j.ijgo.2016.06.026. Epub 2016 Aug 30. Int J Gynaecol Obstet. 2016. Retraction in: Int J Gynaecol Obstet. 2024 Aug;166(2):914. doi: 10.1002/ijgo.15694. PMID: 27614789 Retracted. Clinical Trial.
Cited by
-
The Role of Uterine Natural Killer Cells on Recurrent Miscarriage and Recurrent Implantation Failure: From Pathophysiology to Treatment.Biomedicines. 2021 Oct 9;9(10):1425. doi: 10.3390/biomedicines9101425. Biomedicines. 2021. PMID: 34680540 Free PMC article. Review.
-
Evaluating the Utility of Intralipid Infusion to Improve Live Birth Rates in Patients with Recurrent Pregnancy Loss or Recurrent Implantation Failure.J Hum Reprod Sci. 2018 Jul-Sep;11(3):261-268. doi: 10.4103/jhrs.JHRS_28_18. J Hum Reprod Sci. 2018. PMID: 30568356 Free PMC article.
-
Are uterine natural killer and plasma cells in infertility patients associated with endometriosis, repeated implantation failure, or recurrent pregnancy loss?Arch Gynecol Obstet. 2020 Dec;302(6):1487-1494. doi: 10.1007/s00404-020-05679-z. Epub 2020 Jul 14. Arch Gynecol Obstet. 2020. PMID: 32666129 Free PMC article.
-
Intralipid therapy and adverse reproductive outcome: is there any evidence?Reprod Fertil. 2021 Jun 3;2(3):173-186. doi: 10.1530/RAF-20-0052. eCollection 2021 Jul. Reprod Fertil. 2021. PMID: 35118388 Free PMC article.
-
Adjuvants in IVF-evidence for what works and what does not work.Ups J Med Sci. 2020 May;125(2):144-151. doi: 10.1080/03009734.2020.1751751. Epub 2020 May 7. Ups J Med Sci. 2020. PMID: 32378442 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical